Ivosidenib for advanced IDH1-mutant cholangiocarcinoma – Authors' reply - ScienceDirect

The Lancet Oncology

Volume 21, Issue 8, August 2020, Page e371

The Lancet Oncology

https://doi.org/10.1016/S1470-2045(20)30394-6 Get rights and content

Reference (1)

GK Abou-Alfa et al.
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Lancet Oncol
(2020)

Cited by (3)

CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinoma
2024, Molecular Cancer
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications
2023, Gut
Cholangiocarcinoma
2021, Nature Reviews Disease Primers

© 2020 Elsevier Ltd. All rights reserved.